New targets in pediatric acute myeloid leukemia

Research output: Contribution to journalArticlepeer-review


In the last few years the improvements of chemotherapy regimens and supportive care has progressively ameliorated the prognosis of children suffering from Acute Myeloid Leukemia (AML). However, a still high percentage of children do not respond to first line treatments or relapse and need to undergo further treatments. The need to explore new agents other than chemotherapy has been highlighted in the last years in order to overcome drug related resistance and toxicity. Recently, novel therapies have been studied within early phases pediatric trials and seem to show encouraging results. In fact, the knowledge of molecular abnormalities related to AML pathogenesis has permitted to identify selective drugs that may represent an important tool for the development of patient-tailored treatments. Nowadays, FLT3, Aurora Kinases, mTORS's and proteasome inhibitors represents the most promising drugs that are being used in pediatric AML studies.

Original languageEnglish
Pages (from-to)47-50
Number of pages4
JournalImmunology Letters
Issue number1-2
Publication statusPublished - Sep 2013


  • Acute Myelod Leukemia
  • Children
  • Therapeutic advances

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'New targets in pediatric acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this